Abstract: The present invention relates to pharmaceutical compositions comprising therapeutic combinations comprising: one or more H3 antagonists/inverse agonists; one or more appetite suppressants selected from the group consisting of CB1 antagonists/inverse agonists, sibutramine, phentermine and topiramate; and optionally one or more HMG-CoA reductase inhibitors. The invention also relates to medicaments and kits comprising the pharmaceutical compositions of the present invention, and methods of treating obesity, obesity related disorders and diabetes using the pharmaceutical compositions of the present invention.

Abstract: In its many embodiments, the present invention provides a novel class of indolines as inhibitors of ?2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the ?2C adrenergic receptors using such compounds or pharmaceutical compositions.

Abstract: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as ?2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the ?2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.

Abstract: The present invention discloses the compound of Formula I and pharmaceutically acceptable salts and solvates thereof. The invention also relates to pharmaceutical compositions comprising the Compound of Formula I and its use in treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease. The invention also relates to the use of a combination of the Compound of Formula I with additional therapeutic agents for treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease.

Abstract: Methods and systems are provided for lighting systems, including high output linear lighting systems for various environments. The linear lighting systems may include power systems for driving light sources in high-voltage environments.

Abstract: Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M1 and M3 are CH or N; M2 is CH, CF or N; Y is —C(?O)—, —C(?S)—, —(CH2)q—, —C(?NOR7)— or —SO1-2—; Z is a bond or optionally substituted alkylene or alkenylene; R1 is H, or alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, all optionally substituted, or a group of the formula: where ring A is a heteroaryl ring; R2 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; R3 is H, —C(O)NH2, or alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl, all optionally substituted; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders using said compounds, alone or in combination with other age

Abstract: Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M1 and M3 are CH or N; M2 is CH, CF or N; Y is —C(?O)—, —C(?S)—, —(CH2)q—, —C(?NOR7)— or —SO1-2—; Z is a bond or optionally substituted alkylene or alkenylene; R1 is H, alkyl, alkenyl, or optionally substituted cycloalkyl, aryl, heteroaryl, heterocycloalkyl or a group of the formula: where ring A is a monoheteroaryl ring; R1 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma or cognition deficit disorders using said compounds, alone or in combination with other agents.

Abstract: Modular lighting fixtures that allow convenient installation and removal of LED-based light-generating modules and controller modules. In one example, a modular lighting fixture includes a housing configured to be recessed into or disposed behind an architectural surface such as ceiling, wall, or soffit, in new or existing construction scenarios. The fixture housing includes a socket configured to facilitate one or more of a mechanical, electrical and thermal coupling of the light-generating module to the fixture housing. The ability to easily engage and disengage the LED-based light-generating module with the socket, without removing the fixture housing itself, allows for straightforward replacement of the light-generating module upon failure, or exchange with another module having different light-generating characteristics.

Abstract: Modular lighting fixtures that allow convenient installation and removal of LED-based light-generating modules and controller modules. In one example, a modular lighting fixture includes a housing configured to be recessed into or disposed behind an architectural surface such as ceiling, wall, or soffit, in new or existing construction scenarios. The fixture housing includes a socket configured to facilitate one or more of a mechanical, electrical and thermal coupling of the light-generating module to the fixture housing. The ability to easily engage and disengage the LED-based light-generating module with the socket, without removing the fixture housing itself, allows for straightforward replacement of the light-generating module upon failure, or exchange with another module having different light-generating characteristics.

Abstract: A device is claimed for passively dispensing sanitizing tablets in a container of water. Preferably the invention is applied to dispensing sanitizing tablets in a toilet tank, and means are described for positioning the device and controlling the amount of sanitizer dispensed per flush.

Abstract: A switching power supply is modified to mitigate potentially adverse effects of near zero loads on power delivery. In one example, a processor-controlled dummy load is coupled to the power supply output in addition to an actual load. The dummy load is controlled so that at least some minimal load is presented to the power supply when the actual load is drawing low or near zero power. In another example, the feedback loop of the switching power supply is modified to mitigate the effects of a potential overvoltage condition in a bias supply from which the switch controller of the power supply draws power, which condition may occur at low or near zero load power. A lighting system may include a switching power supply thusly modified to provide power to a variable load that includes one or more LED-based lighting apparatus.

Abstract: Methods and systems are provided for lighting systems, including high output linear lighting systems for various environments. The linear lighting systems may include power systems for driving light sources in high-voltage environments.

Abstract: Methods and systems are provided for lighting control, including a lighting system manager, a light show composer, a light system engine, and related facilities for the convenient authoring and execution of lighting shows using semiconductor-based illumination units.

Abstract: Methods and systems are provided for lighting systems, including high output linear lighting systems for various environments. The linear lighting systems may include power systems for driving light sources in high-voltage environments.

Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.

Abstract: Toys and consumer products may be configured to provide one or more perceivable output modalities/conditions that may be sensed by a human (e.g., light and/or sound), in response to one or more monitored (input) conditions, to facilitate some form of interactivity between the toy/product and one or more users/observers of the toy/product. In one example, a toy/product is configured with one or more light emitting diodes (LEDs) that are controlled to provide one or more colors and/or patterns of light as a function of a sensed condition relating to motion and/or impact of the toy/product (e.g., velocity, acceleration, centrifugal force, impact or other measured response). More generally, a toy/product can be thrown, rotated, made to whirl or otherwise move, touched or otherwise impacted, and the toy/product can be configured to react as a function of velocity, acceleration, centrifugal force, impact or other measured response by producing one or more perceivable conditions.